At Ancora.ai, we work with best-in-class physicians, patient associations, and scientific experts to bridge the gap between innovations in medicine and patients. Radiopharmaceuticals are a rapidly evolving and promising field that has recently experienced a surge in investment and research. That’s why we’re so excited to share that on Oct. 20th we’re launching our Radiopharmaceutical Trials Platform in collaboration with WARMTH (https://warmth.org/) and with funding by ICPO Foundation-International Centers for Precision Oncology. The Radiopharmaceutical Trials Platform lets you explore #radiopharmaceutical trials from across the world by radiation emission type, radionuclide, target and more! A huge thank you to our scientific advisors and their valuable contributions to the project: Prof. Ken Herrmann, Prof. Andrew Scott, Elcin Zan, MD, Dr. Masha Maharaj, Dr. Kalevi Kairemo, Dr. Sze Ting Lee, Bonnie Clarke, Dr. Cathy Cutler, and Dr. Michael Hofman The official launch is on Oct. 20th, 2024 at the European Association of Nuclear Medicine (EANM) Congress. Stop by the ICPO booth at EANM (HALL 3, S33) to get a demo and/ or sign up below to be notified when the platform is live: https://lnkd.in/dnsW2Guk Lastly, a huge thank you to all the project members and their support: Josh Mailman, Odile JAUME, Susanne Simon, Karim Bouterfa, and Andreas Noetzold, Katie Vieyra, Danielle Ralic, Beatriz M. Monreal, Marko Buterin, mag. inf., Zvonimir Dražina. #clinicaltrials #clinicalresearch #nuclearmedicine #oncology #healthtech #innovation #AI #AIinhealthcare
Ancora.ai’s Post
More Relevant Posts
-
Meet the newest addition to the Invicro team, Dr. Paolo Zanotti Fregonara, MD, PhD, Senior Director, Oncology Image Analysis, at booth #1822 during #SNMMI24! Dr. Zanotti Fregonara is a board-certified nuclear medicine physician and an expert in PET methodology with a focus on kinetic modeling and dosimetry. Discover how Invicro is revolutionizing healthcare with comprehensive #radiopharmaceutical therapy and #theranostic solutions. From #radiochemistry to advanced image analytics and #dosimetry, learn how we empower research and transform healthcare. #Radioligandtherapy #Meettheteam #Dosimetry
-
-
PanMediso Spotlight｜What Are Radiopharmaceuticals? Radiopharmaceuticals are special drugs containing radioactive isotopes, used in medical diagnosis and treatment. For instance, Technetium-99m is widely employed for diagnosing cancer and cardiovascular diseases, while Iodine-131 is used to treat hyperthyroidism. These drugs emit gamma photons or high-energy particles, which, in combination with imaging devices like gamma cameras, SPECT, and PET, assist doctors in observing and treating diseases. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Radiopharmaceutical #Cancer #SPECT #PET #Ac225
-
-
🚀 Exciting Advancement in Neuroendocrine Tumor Treatment! 🚀 Preclinical radiopharmaceutical showdowns will become more common in this developing landscape! This study, published in The Journal of Nuclear Medicine - JNM highlights the efficacy of [67Cu]Cu-EB-TATE theranostic in treating somatostatin receptor subtype-2 (SSTR2)-positive neuroendocrine tumors (NETs). 🔬 Key Highlights 🔬: ☢️Innovative Therapy: [67Cu]Cu-EB-TATE demonstrates superior decay properties and imaging capabilities than the traditionally used [177Lu]Lu-EB-TATE. ☢️Enhanced Effectiveness: In preclinical trials, [67Cu]Cu-EB-TATE showed a 60% success rate in eliminating small tumors (<50 mm³) within 15 days, outperforming [177Lu]Lu-EB-TATE's 20%. ☢️Improved Patient Outcomes: The treatment extended mean survival significantly, with treated groups showing survival times of over 90 days, compared to 26-53 days for control groups. This research, led by Fabrice Ngoh Njotu and team, positions [67Cu]Cu-EB-TATE as a promising candidate for clinical development, #NuclearMedicine #NeuroendocrineTumors #Theranostics #MedicalResearch #HealthcareInnovation #CancerTreatment
-
PanMediso Spotlight｜Applications and Advantages of 68Ga in PET Imaging 68Ga (Gallium-68) is a widely used radionuclide in the field of nuclear medicine, particularly suited for positron emission tomography (PET) imaging. It does not require on-site cyclotron preparation and has a half-life of 68 minutes, with a positron decay rate of 89%. 68Ga-labeled radiopharmaceuticals are extensively applied in tumor imaging, including prostate cancer, neuroendocrine tumors (NENs), and for the diagnosis and staging of malignant tumors. Additionally, they are used in imaging for myocardial perfusion, lung perfusion, as well as inflammation and infection. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Radiopharmaceutical #68Ga #PET #prostatecancer #NENs
-
-
🔬 Join ICON plc's upcoming webinar on imaging and therapeutic dosimetry in precision nuclear medicine! Dosimetry is key to treatment planning in radioligand therapy, estimating the absorbed radiation dose to optimize biological effects while minimizing damage to healthy tissue. The complexities of radiopharmaceutical interactions demand sophisticated dosimetric processes, offering insights like lesion dose-response correlations and dose-volume histograms that enhance the correlation between biological effects and clinical outcomes. ➡️ Register to learn how dosimetry is transforming radiation-based treatments for better patient outcomes: https://buff.ly/4dvVm5K #DrugDevelopment #PrecisionMedicine #ClinicalResearch #Oncology #Radiology #TherapeuticAreas #Radiotherapy #Radiopharmaceuticals #OncologyDrugDevelopment #Dosimetry #Radioligand
-
-
𝐑𝐚𝐝𝐢𝐚𝐭𝐢𝐨𝐧 𝐃𝐨𝐬𝐞 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $654 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 13.8% 𝐛𝐲 2028 📚 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/d_8Cg3Cp Across the globe, an increasing number of oncology and nuclear medicine procedures are being performed owing to their high imaging efficiency. According to WHO, cancer is leading cause of death. Annually, 19.3 million new cancer cases are expected to be reported worldwide by 2025. #NorthAmerica accounted for the largest share of the radiation dose management market. The region's robust growth is attributed to substantial healthcare IT expenditures, coupled with a high penetration of innovative radiation software solutions. 🌐 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Bayer GE HealthCare Philips Siemens Healthcare Pvt. Ltd. FUJIFILM Holdings Corporation Canon Inc. PACSHealth LLC Sectra Bracco Imaging Korea QAELUM AGFA HealthCare Novarad MEDIC VISION Guerbet Medsquare INFINITT Healthcare Volpara Health Medic Vision Imaging Solutions Imalogix Dedalus Nanjing Perlove Medical Equipment Co.,ltd Mirion Technologies (Dosimetry Services) B.V., LANDAUER Polimaster Fortive
-
-
Excited to share our next publication in The Journal of Nuclear Medicine - JNM, led by Dr. Ramesh Mukkamala! He is a fantastic synthetic and medicinal chemist, as well as a rising star in the field of targeted radiopharmaceuticals. It was my privilege to collaborate with him on this project featuring important discoveries on novel ligands for FAP-targeted radiopharmaceuticals during our time together in the lab of Professor Philip Low. Also, a big congratulations to my former undergraduate assistants and fellow co-authors, Pooja Tudi, Taylor Schleinkofer, and Owen Booth! See below to download and read the full paper. #FAP #TargetedRadiopharmaceuticals #TRP
I am thrilled to share that my work on fibroblast activation protein-targeted radioligand therapy has been published in The Journal of Nuclear Medicine (JNM). https://lnkd.in/gqMsSwyg. In this article, we report that the key fundamental aspects important for effective radioligand therapy, such as high tumor uptake, retention, and tumor-to-healthy tissue ratios, have been significantly improved with our novel FAP-targeted radioligand. I would like to thank all my co-authors, without whom this work would not have been possible to publish. I extend my deepest gratitude to my supervisor, Philip Low, for the wonderful opportunity to work in this fascinating research field and for his critical mentorship. I am also grateful to my friends and colleagues Dr. Spencer D. Lindeman, Dr. Madduri Srinivasarao, and Dr. Abigail Cox for their support and intellectual expertise, which were instrumental in the success of this work. Last but not least, I would like to thank our undergraduate students—Daniel J. Carlson, Nicholas Kaine Miller, Emily Renee Bowen, Pooja Tudi, Taylor Schleinkofer, and Owen C. Booth for their sincere and unwavering efforts.
Design of a Fibroblast Activation Protein–Targeted Radiopharmaceutical Therapy with High Tumor–to–Healthy-Tissue Ratios
jnm.snmjournals.org
-
PanMediso Spotlight｜Another MNC Joins the Radiopharmaceutical Race with a €320 Million Deal On September 12, 2024, Sanofi reached an exclusive licensing agreement valued at approximately €320 million with RadioMedix and Orano Med to co-develop radioligand therapy (RLT) based on the radioactive isotope 212Pb for cancer treatment. The core of the collaboration is the AlphaMedix project, an alpha particle-targeted therapy (TAT) designed to treat patients with neuroendocrine tumors (NET) expressing somatostatin receptors. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Radiopharmaceutical #Cancer #Sanofi #RadioMedix #OranoMed #212Pb #RLT #AlphaMedix
-
-
Is the future of healthcare Vertical or Horizontal? Just back from the American Society for Radiation Oncology (ASTRO) Congress and it's clear that #Prostate #Cancer is a major focus and business in radiation therapy right now. Along with the latest RT technologies showcased by the big players like Accuray, Elekta, and Varian, many solutions at the technical exhibit were typically not the core focus of Radiation Oncologists. To name a few, there were IVD solutions for risk stratification (many using AI), #PSMA PET radiotracers for staging and biochemical recurrence diagnosis from Lantheus and Telix Pharmaceuticals Limited & Lu-177 radiopharmaceuticals for treatment from Novartis Advanced Accelerator Applications (yes, these are “radiation”, but usually managed by the nuclear medicine department), and even non-ionizing modalities like HistoSonics, Inc.' histotripsy technology! This trend highlights how radiation oncologists are expanding their horizons to adopt solutions beyond their traditional expertise. A pattern that is seen with other clinical specialties as well. What do you think about the future of healthcare? Will we see more disease-specific specialists 🎯 and a shift towards a more vertically integrated approach, or will technical specialists 👨🔬 continue to dominate the field? #ASTROCongress #RadiationTherapy #ProstateCancer #Healthcare #MedicalTechnology #Innovation
-
